Biotech is notoriously risky. The odds of a drug getting FDA approval are staggeringly low, and even then companies aren’t in the clear. Investors might just think biotech is just way too risky to bother with… but it doesn’t have to be.

In this week’s episode of Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Brian Feroldi share three methods that can get you exposure to biotechstyle gains without taking on so much of that goingtozeroovernight risk. Listen in to hear the pros and cons to investing in sectorwide ETFs, contract research organizations, and picks and shovels plays plus, of course, some companies to add to your watchlist in each of those categories.

Subscribe to The Motley Fool's YouTube Channel:
   / themotleyfool  
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/p...

Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
  / themotleyfool  
Follow The Motley Fool on Twitter:
  / themotleyfool